<?xml version="1.0" encoding="UTF-8"?>
<p>TMC353121, a small substituted benzimidazole RSV fusion inhibitor, is an improved derivative of JNJ-2408068 [a compound with antiviral activity against both RSV A and B, but with long tissue retention times in animal models which created concerns and stopped its further development (
 <xref rid="ref164" ref-type="bibr">Wyde et al., 2003</xref>; 
 <xref rid="ref20" ref-type="bibr">Bonfanti et al., 2007</xref>)].TMC353121, in contrast to JNJ-2408068, lacks the long tissue retention but maintains its high antiviral activity 
 <italic>in vitro</italic> (
 <xref rid="ref21" ref-type="bibr">Bonfanti et al., 2008</xref>). Using TMC353121 in preclinical studies in cotton rats (
 <xref rid="ref122" ref-type="bibr">Rouan et al., 2010</xref>) and African green monkeys (
 <xref rid="ref70" ref-type="bibr">Ispas et al., 2015</xref>) revealed a reduction in viral loads in a dose-dependent manner and in lung inflammation. Based on these data, TMC353121 could be a drug candidate for treatment of RSV infection; however, safety studies and more clinical evaluations are still needed.
</p>
